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Copyright © 2011 JCBN 2011 This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. We examined whether continuous supplementation with branched 
chain amino acids phosphorylates ribosomal protein S6, a down 
stream effector of mammalian target of rapamycin, and improves
hypoalbuminemia of rats with chronic liver disease. Sprague 
Dawley rats were fed a casein diet (control group) or a branched 
chain amino acid supplemented casein diet (branched chain amino
acid group) for 11 weeks with repeated injections of carbon
tetrachloride. Throughout this experimental period, no significant
difference in plasma albumin concentration was seen between
groups. The percentage of reduced albumin within total plasma
albumin gradually decreased in both control and branched chain
amino acid groups. After 11 weeks with supplementation, phos 
phorylation of ribosomal protein S6 was significantly increased in
the liver of rats in the branched chain amino acid group compared
with the control group. Furthermore, the percentage of reduced
albumin within total albumin was significantly higher in the
branched chain amino acid group than in the control group. These
results indicate that continuous supplementation with branched 
chain amino acids in rats with chronic liver disease induces phos 
phorylation of hepatic ribosomal protein S6 and attenuates
decreases in the percentage of reduced albumin, although levels
of plasma albumin are not increased.
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Introduction Plasma amino acid imbalances, including a decrease in the
concentration of branched-chain amino acids (BCAAs), an
increase in aromatic amino acids (AAAs), and a subsequent
reduction in the molar ratio of BCAAs to AAAs, are characteristic
of patients with liver cirrhosis.(1,2) In addition, the reduction of
BCAA/AAA ratio correlated strongly with the reduction of plasma
proteins, including albumin, transferrin, prealbumin and retinol-
binding protein.(3) A high prevalence of hypoalbuminemia is seen
among patients with chronic hepatic failure, including patients
with decompensated liver cirrhosis.(4–6) Survival rates are lower in
cirrhotic patients with hypoalbuminemia compared with patients
showing normal albumin concentrations (>3.5 g/dL).(7)
Albumin displays microheterogeneity, including oxidized and
reduced forms of albumin.(8) Human mercaptalbumin (HMA,
reduced albumin) has a free thiol form in the cysteine residue at
the 34th position from the N-terminal. On the other hand, the
cysteine residue in human nonmercaptalbumin (HNA, oxidized
albumin) forms a disulfide with small thiol compounds, mainly
cysteine or cysteinylglycine (HNA1) or is oxidized with a sulfinic
(−SO2H) or sulfonic (−SO3H) acid (HNA2). The percentage of
HNA within total albumin is about 30% in serum from healthy
subjects.(9) In cirrhotic patients, both albumin synthesis and degra-
dation rates of albumin are decreased, and the biological half-life
of albumin is prolonged.(7) As a result, the percentage of HNA
within total albumin increases with the progression of liver
cirrhosis.(9) In Japan, pharmacological supplementation with
BCAAs is widely used to improve hypoalbuminemia in patients
with decompensated liver cirrhosis.(10,11) Previous studies have
reported that the decreased synthesis and degradation rates and
abnormal oxidized/reduced state of albumin can be improved in
cirrhotic patients with BCAA supplementation.(7,12)
L-leucine, one of the BCAA components, can activate mamma-
lian target of rapamycin (mTOR) signaling, which is critical for
protein synthesis at the level of translational initiation.(13,14) Acti-
vated mTOR phosphorylates p70 S6 kinase, followed by activated
p70 S6 kinase that phosphorylates ribosomal protein S6, and as a
result, increases the protein synthesis complex. Activated mTOR
also phosphorylates 4E-BP1 and promotes the formation of the
protein synthesis initiation complex. Previous studies have
suggested that addition of leucine to culture medium promotes
albumin synthesis in rat primary hepatocytes(15) and the HepG2
human cell line(16) via the activation of mTOR signaling. Further-
more, oral administration of BCAAs reportedly activates mTOR
signaling in the liver of rats with chronic liver disease.(17) However,
in that animal experiment, activation of mTOR signaling was
evaluated under transient administration of a large amount of
BCAAs. This means that evidence is lacking that continuous
supplementation with BCAAs as seen in clinical scenarios for
cirrhotic patients activates mTOR signaling in the liver of cirrhotic
model animals. The present study investigated whether continuous
supplementation with BCAAs in rats with chronic liver disease
influenced the activation of hepatic mTOR signaling and the
oxidized/reduced ratio of plasma albumin.
Materials and Methods
Animals. The animal facilities and protocol were reviewed and
approved by the Institutional Animal Care and Use Committee at
Kyoto Prefectural University. Male Sprague-Dawley rats (weight,
about 200 g) were housed under a 12-h light/dark cycle, with ad
libitum access to commercial diet and water. Chronic liver disease
was induced by injection of carbon tetrachloride (CCl4) (Wako
Pure Chem., Osaka, Japan). Briefly, after an acclimatization
period of 1 week, CCl4 mixed with an equal volume of olive oil
was injected subcutaneously twice a week at a dose of 1.0 mL/kg
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of body weight for 11 weeks. During this experimental period,
rats were divided into 2 groups and fed either the casein diet
(control group, n = 5) or the BCAA-supplemented casein diet
(BCAA group, n = 6) (Table 1). Rats were given ad libitum access
to the diet and drinking water. Dietary intake and body weight
were measured every day during the experimental period. Blood
was drawn from the tail vein every week and centrifuged to
separate plasma. After 11 weeks, each rat was anesthetized with
diethyl ether. Blood was drawn and centrifuged to separate
plasma. The liver was rapidly removed and weighed. Plasma and
liver samples were stored at −70°C until analysis.
Measurement of plasma aminotransferase, total protein
and albumin. Plasma concentrations of aspartate aminotrans-
ferase, alanine aminotransferase, total protein and albumin were
measured using GOT-L, GPT-L, TP-L and BCG-L kits (Cerotec,
Sapporo, Japan), respectively. Samples were analyzed using a
CL-8000 autoanalyzer (Shimadzu, Kyoto, Japan).
Measurement of plasma amino acids. Plasma was de-
proteinized with ethanol and the supernatant was used for amino
acid analysis by high-performance liquid chromatography (HPLC)
using a precolumn phenylisothiocyanate derivatization technique.(18)
Norleucine was used as an internal standard. The molar ratio
of BCAAs to AAAs was calculated as (Valine + Leucine +
Isoleucine) / (Phenylalanine + Tyrosine).
Histological examination. Small pieces of each liver were
fixed in 10% buffered formaldehyde then embedded in paraffin.
Paraffin sections (3 μm thick) were stained with Azan stain to
observe liver fibrosis. Sections were imaged using a microscope
(Olympus Co., Tokyo, Japan).
Western blot analysis. Western blot analysis using anti-S6
and anti-phospho-S6 antibodies (Ser 235/236) (Cell Signaling
Technology, Danvers, MA) was performed as described pre-
viously.(16) Briefly, the liver was homogenized in buffer containing
20 mM HEPES (pH 7.4), 100 mM KCl, 0.2 mM EDTA, 2 mM
EGTA, 1 mM DTT, 50 mM NaF, 50 mM β-glycerophosphate,
0.1 mM PMSF, 1 mM benzamidine and 0.5 mM sodium vanadate.
Homogenates were centrifuged at 8,000 × g for 30 min at 4°C.
The resulting supernatant fraction was subjected to western blot
analysis. The protein concentration was determined using BCA
protein assay reagent (Pierce, Rockford, IL).
Analysis of the oxidized/reduced state of albumin.
HPLC was performed using method described by Hayashi et al.(19)
The HPLC system consisted of a #3023 autosampler (injection
volume, 0.5 μL), #3101 pumps and a #3213 fluorescence detector
(excitation wavelength, 280 nm; emission wavelength, 340 nm)
in conjunction with a S-MC system controller (all from Shiseido,
Tokyo, Japan). An ES-502N ion-exchange column (Shodex-
Asahipak) (Showa Denko K.K., Kawasaki, Japan) was used.
Measurements were carried out by solvent gradient elution with
increasing ethanol concentration from 0% to 10% in 50 mM
sodium acetate and 400 mM sodium sulfate (pH 4.85) at a flowrate
of 1.0 mL/min.
Statistical analysis. Data are expressed as mean ± standard
error of the mean (SEM). The uniformity of standard deviation
within groups was evaluated using the F-test. The significance of
differences was assessed using Student’s t test. Statistical analysis
for multiple comparisons was performed using one-way analysis
of variance followed by a Tukey-Kramer post hoc test. Data
analysis was performed using Statcel2 software (Oms Publishing,
Tokyo, Japan) and values of p<0.05 were considered statistically
significant.
Results
In the experimental period, no significant differences in plasma
albumin levels were seen between control and BCAA groups
(Fig. 1A). The percentage of reduced albumin gradually decreased
from 4 weeks in both control and BCAA groups (Fig. 1B).
However, the decrease in reduced albumin was more marked in
the control group than in the BCAA group.
No significant differences in food intake, final body weight or
liver weight were seen between control and BCAA groups
(Table 2). In terms of blood biochemistry, no significant differ-
ences in aminotransferase activities, total protein or albumin
Table 1. Composition of test diets
1AIN 76 vitamin mixture. 2AIN 76 mineral mixture.
(g/kg diet)
Component Control diet BCAA diet
Casein 200 175
Valine 0 7
Leucine 0 12
Isoleucine 0 6
Cornstarch 457 457
Sucrose 228 228
Rapeseed oil 35 35
Soybean oil 15 15
Cellulose 20 20
Vitamin mixture1 10 10
Mineral mixture2 35 35
Fig. 1. Effect of BCAA supplementation on levels of plasma albumin
and percentages of reduced albumin in CCl4 treated rats. CCl4 treated
rats were fed either the control diet (control group, closed circles) or
the BCAA supplemented diet (BCAA group, open circles) for 11 weeks.
Blood was drawn from the tail vein every week. Plasma albumin levels
were monitored (A) and percentages of reduced albumin within total
albumin were analyzed by HPLC (B). HPLC was performed using an ES 
502N ion exchange column with an increasing ethanol concentration
from 0% to 10% in 50 mM sodium acetate and 400 mM sodium sulfate
buffer (pH 4.85). Values represent means ± SEM (n =3 ) . J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 69
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concentrations were seen between groups (Table 2). CCl4-treated
rats developed liver fibrosis (Fig. 2). However, the liver fibrosis
was mild in the BCAA group compared with the control group.
Plasma valine and leucine levels were significantly higher in the
BCAA group than in the control group (Table 3). As a result,
plasma BCAA levels were significantly higher in the BCAA
group than in the control group (Table 3). No significant differ-
ences in plasma AAA levels were seen between groups (Table 3).
The molar ratio of BCAAs to AAAs was significantly higher in
the BCAA group than in the control group (Table 3). Phosphoryla-
tion of ribosomal protein S6, a downstream effector of mTOR,
was remarkably decreased in CCl4-treated rats compared with
normal rats (Fig. 3). However, phosphorylation of ribosomal
protein S6 was significantly increased in the BCAA group com-
pared with the control group.
Fig. 4 shows typical HPLC profiles of plasma albumin. In
plasma from normal rats, percentages of reduced albumin and
oxidized albumin within total albumin were 72.5 ± 0.8% and
27.5 ± 0.8%, respectively (n = 3) (Fig. 4A). In plasma from rats
treated with CCl4 for 11 weeks, percentages of reduced albumin
and oxidized albumin within total albumin were 51.6 ± 2.4% and
48.4 ± 2.4%, respectively, in the control group (Fig. 4B), and
62.8 ± 3.0% and 37.3 ± 3.0%, respectively, in the BCAA group
(Fig. 4C). The percentage of reduced albumin was significantly
higher in the BCAA group than in the control group (Fig. 5).
Discussion
Long-term nutritional supplementation with oral BCAAs
improves hypoalbuminemia in patients with liver cirrhosis.(11) The
mechanism by which BCAAs improve hypoalbuminemia has
been thought to involve promotion of albumin synthesis via
Table 2. Food intake, body weight, liver weight and blood biochemistry
in CCl4 treated rats fed control or BCAA supplemented diets for 11
weeks
Values are given as means ± SEM (Control, n = 5; BCAA, n = 6). AST,
aspartate aminotransferase; ALT, alanine aminotransferase.
Control BCAA
Food intake (g/day) 19 ± 12 1 ± 1
Body weight (g) 365 ± 18 404 ± 16
Liver weight (g) 15.3 ± 1.0 19.9 ± 1.8
Blood biochemistry
AST (IU/L) 916 ± 93 586 ± 138
ALT (IU/L) 455 ± 98 522 ± 208
Total protein (g/dL) 5.1 ± 0.1 5.6 ± 0.2
Albumin (g/dL) 2.7 ± 0.1 2.9 ± 0.1
Table 3. Plasma BCAA and AAA concentrations in CCl4 treated rats fed
control or BCAA supplemented diets for 11 weeks
Values are given as means ± SEM (Control, n = 3; BCAA, n = 5). *p<0.05.
(nmol/mL)
Control BCAA
Valine 208 ± 34 325 ± 15*
Leucine 140 ± 25 219 ± 13*
Isoleucine 128 ± 71 2 7 ± 11
BCAA 476 ± 62 671 ± 38*
Tyrosine 126 ± 21 118 ± 18
Phenylalanine 66 ± 11 68 ± 9
AAA 192 ± 32 186 ± 27
BCAA/AAA molar ratio 2.5 ± 0.2 3.8 ± 0.3*
Fig. 3. Effect of BCAA supplementation on phosphorylation of
ribosomal protein S6 in livers of CCl4 treated rats. CCl4 treated rats
were fed either the control diet (control group) or the BCAA supple 
mented diet (BCAA group) for 11 weeks. Normal rats were fed the
control diet for 11 weeks. The phosphorylation of hepatic ribosomal
protein S6 was analyzed by western blot using anti phospho S6 (P S6)
and anti S6 (S6) antibodies. The corresponding densitometric analysis is
shown. Values are given as mean ± SEM (normal, n = 3; control group,
n = 5; BCAA group, n = 6). Means not sharing the same letter are
significantly different from each other, p<0.05.
Fig. 2. Effect of BCAA supplementation on liver fibrosis in CCl4 treated
rats. CCl4 treated rats were fed either the control diet (control group) or
the BCAA supplemented diet (BCAA group) for 11 weeks. Representa 
tive Azan staining sections from liver of rats in control (A) and BCAA (B)
groups are shown (Original magnification ×40).doi: 10.3164/jcbn.11 37
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activation of hepatic mTOR signaling.(15,16) Oral administration of
BCAA reportedly induces phosphorylation of p70 S6 kinase and
4E-BP1 in livers of both normal(20–22) and cirrhotic rats.(17) When
starved rats were administered BCAA, phosphorylation of p70 S6
kinase and 4E-BP1 reached maximum levels within 1 h and
returned to baseline levels within 6 h after administration.(17,21) All
these studies therefore examined the effects of transient admin-
istration of BCAAs on hepatic mTOR signaling in food-deprived
(16–24 h) rats.(17,20–22) Conversely, our previous study showed
that phosphorylation of ribosomal protein S6 could be detected
through mTOR signaling in the livers of rats fed freely.(23) To the
best of our knowledge, the present results comprise the first
reported evidence that continuous supplementation with BCAAs
induced phosphorylation of ribosomal protein S6 in the livers of
rats with chronic liver disease.
The decrease in the percentage of reduced albumin was
attenuated in the plasma of CCl4-treated rats following BCAA
supplementation. A recent study suggested that BCAA supple-
mentation increases the expression of genes involved in anti-
oxidant defense and reduces the production of reactive oxygen
species in cardiac and skeletal muscles, but not in the liver of
middle-aged mice.(24) In the present study, no significant differ-
ence in oxygen radical absorbance capacity in plasma was seen
between the control and BCAA groups (data not shown). However,
we cannot exclude the possibility that BCAA supplementation
increased the percentages of reduced albumin in the plasma of
CCl4-treated rats by activating antioxidative mechanisms rather
than the albumin synthesis system.
In HPLC analysis of human albumin, three peaks are detected
in the order of HMA, HNA1, and HNA2.(8,12) In plasma albumin
from healthy subjects, HMA accounts for 70% and HNA1 for
30%, with HNA2 only barely apparent. In the present study, the
second peak that corresponded to HNA1 was small, and the third
peak corresponding to HNA2 was large in plasma albumin from
normal rats. Future studies need to determine detailed structures of
the rat albumin in these peaks. BCAA supplementation in cirrhotic
patients significantly increased HMA and significantly decreased
HNA1, although HNA2 did not show significant change.(12) The
HPLC profiles of the BCAA group in the present study seem to
correspond to the result for patients supplemented with BCAAs.
The increase in percentages of reduced albumin may thus improve
albumin function, including ligand-binding properties and anti-
oxidant activity.(25)
In the present study, the concentration of plasma albumin did
not differ significantly between control and BCAA groups,
probably because the experimental period was short. However,
continuous supplementation with BCAAs for rats with chronic
liver disease induced the phosphorylation of ribosomal protein
S6 in liver and improved the oxidized/reduced ratio of plasma
albumin. Albumin molecules will structurally change the reduced
form to the oxidized form for the extended half-life of albumin in
cirrhotic patients.(7) Supplementation with BCAAs may improve
abnormal albumin metabolism through the activation of albumin
synthesis. Actually, analyzing the oxidized/reduced ratio of
plasma albumin with every clinical examination in hospital will be
difficult. However, if a molecule can be found that reflects the
Fig. 4. Typical HPLC profiles of plasma albumin from normal rats (A)
and CCl4 treated rats that were fed the control diet (B) or the BCAA 
supplemented diet (C) for 11 weeks. HPLC conditions were the same as
those in Fig. 1B.
Fig. 5. Effect of BCAA supplementation on percentages of reduced
albumin within total albumin in plasma of CCl4 treated rats. CCl4 
treated rats were fed either the control diet (control group) or the
BCAA supplemented diet (BCAA group) for 11 weeks. Plasma albumin
was analyzed by HPLC. HPLC conditions were same as those in Fig. 1B.
Values are given as means ± SEM (control group, n = 5; BCAA group,
n =6 ) .  * p<0.05. J. Clin. Biochem. Nutr. | January 2012 | vol. 50 | no. 1 | 71
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oxidized/reduced ratio of plasma albumin in cirrhotic patients,
such a molecule might offer a new marker to evaluate the effects
of BCAA treatment.
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Abbreviations
AAA aromatic amino acid
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CCl4 carbon tetrachloride
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References
1 Fischer JE, Yoshimura N, Aguirre A, et al. Plasma amino acids in patients
with hepatic encephalopathy. Effects of amino acid infusions. Am J Surg
1974; 127: 40–47.
2 Rosen HM, Yoshimura N, Hodgman JM, Fischer JE. Plasma amino acid
patterns in hepatic encephalopathy of differing etiology. Gastroenterology
1977; 72: 483–487.
3 Muto Y, Yoshida T, Yamatoh M. Clinical assessment of nutritional status in
patients with liver cirrhosis with special reference to plasma amino acid
imbalance. J Clin Biochem Nutr 1986; 1: 89–95.
4 Caregaro L, Alberino F, Amodio P, et al. Malnutrition in alcoholic and virus-
related cirrhosis. Am J Clin Nutr 1996; 63: 602–609.
5 Alberino F, Gatta A, Amodio P, et al. Nutrition and survival in patients with
liver cirrhosis. Nutrition 2001; 17: 445–450.
6 Tajika M, Kato M, Mohri H, et al. Prognostic value of energy metabolism in
patients with viral liver cirrhosis. Nutrition 2002; 18: 229–234.
7 Moriwaki H, Miwa Y, Tajika M, Kato M, Fukushima H, Shiraki M.
Branched-chain amino acids as a protein- and energy-source in liver cirrhosis.
Biochem Biophys Res Commun 2004; 313: 405–409.
8 Oettl K, Marsche G. Redox state of human serum albumin in terms of cysteine-
34 in health and disease. Methods Enzymol 2010; 474: 181–195.
9 Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S. Problems in
serum albumin measurement and clinical significance of albumin micro-
heterogeneity in cirrhotics. Nutrition 2004; 20: 351–357.
10 Sato S, Watanabe A, Muto Y, et al. Clinical comparison of branched-chain
amino acid (L-Leucine, L-Isoleucine, L-Valine) granules and oral nutrition for
hepatic insufficiency in patients with decompensated liver cirrhosis (LIV-EN
study). Hepatol Res 2005; 31: 232–240.
11 Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid
granules on event-free survival in patients with liver cirrhosis. Clin Gastro-
enterol Hepatol 2005; 3: 705–713.
12 Fukushima H, Miwa Y, Shiraki M, et al. Oral branched-chain amino acid
supplementation improves the oxidized/reduced albumin ratio in patients with
liver cirrhosis. Hepatol Res 2007; 37: 765–770.
13 Avruch J, Long X, Ortiz-Vega S, Rapley J, Papageorgiou A, Dai N. Amino
acid regulation of TOR complex 1. Am J Physiol Endocrinol Metab 2009;
296: E592–E602.
14 Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational
control. Nat Rev Mol Cell Biol 2009; 10: 307–318.
15 Ijichi C, Matsumura T, Tsuji T, Eto Y. Branched-chain amino acids promote
albumin synthesis in rat primary hepatocytes through the mTOR signal trans-
duction system. Biochem Biophys Res Commun 2003; 303: 59–64.
16 Kuwahata M, Yoshimura T, Sawai Y, et al. Localization of polypyrimidine-
tract-binding protein is involved in the regulation of albumin synthesis by
branched-chain amino acids in HepG2 cells. J Nutr Biochem 2008; 19: 438–
447.
17 Matsumura T, Morinaga Y, Fujitani S, Takehana K, Nishitani S, Sonaka
I. Oral administration of branched-chain amino acids activates the mTOR
signal in cirrhotic rat liver. Hepatol Res 2005; 33: 27–32.
18 Sarwar G, Botting HG. Rapid analysis of nutritionally important free amino
acids in serum and organs (liver, brain, and heart) by liquid chromatography
of precolumn phenylisothiocyanate derivatives. J Assoc Off Anal Chem 1990;
73: 470–475.
19 Hayashi T, Suda K, Imai H, Era S. Simple and sensitive high-performance
liquid chromatographic method for the investigation of dynamic changes in
the redox state of rat serum albumin. J Chromatogr B Analyt Technol Biomed
Life Sci 2002; 772: 139–146.
20 Anthony TG, Anthony JC, Yoshizawa F, Kimball SR, Jefferson LS. Oral
administration of leucine stimulates ribosomal protein mRNA translation but
not global rates of protein synthesis in the liver of rats. J Nutr 2001; 131:
1171–1176.
21 Yoshizawa F, Sekizawa H, Hirayama S, Hatakeyama A, Nagasawa T,
Sugahara K. Time course of leucine-induced 4E-BP1 and S6K1 phosphoryla-
tion in the liver and skeletal muscle of rats. J Nutr Sci Vitaminol (Tokyo) 2001;
47: 311–315.
22 Reiter AK, Anthony TG, Anthony JC, Jefferson LS, Kimball SR. The mTOR
signaling pathway mediates control of ribosomal protein mRNA translation in
rat liver. Int J Biochem Cell Biol 2004; 36: 2169–2179.
23 Kuwahata M, Kuramoto Y, Sawai Y, et al. Polypyrimidine tract-binding
protein is involved in regulation of albumin synthesis in response to food
intake. J Nutr Sci Vitaminol (Tokyo) 2008; 54: 142–147.
24 D’Antona G, Ragni M, Cardile A, et al. Branched-chain amino acid supple-
mentation promotes survival and supports cardiac and skeletal muscle mito-
chondrial biogenesis in middle-aged mice. Cell Metab 2010; 12: 362–372.
25 Kawakami A, Kubota K, Yamada N, et al. Identification and characterization
of oxidized human serum albumin. A slight structural change impairs its
ligand-binding and antioxidant functions. FEBS J 2006; 273: 3346–3357.